Artis BioSolutions Launches mRNA and Lipid Nanoparticle Manufacturing Capabilities at New “Genetic Medicines Center of Excellence” in Bilbao, Spain
Artis BioSolutions, a company founded to streamline the discovery, development, and production of genetic medicines, today announced the launch of its Genetic Medicines Center of Excellence in Bilbao, Spain. The new center expands the company's integrated development and manufacturing capabilities, strengthening its position as a leading technology innovator and manufacturer for next-generation genetic medicines.
Landmark Bio and Syngoi Technologies to Operate as Artis BioSolutions, an End-to-end Gene-to-GMP Platform for Genetic Medicines
Artis BioSolutions, an advanced therapies company built to streamline the discovery, development, and production of genetic medicines, today announced that both Landmark Bio, its Watertown, Massachusetts-based development and GMP manufacturing operation, and Syngoi, its Bilbao, Spain-based enzymatic synthetic DNA business, will now operate under the Artis BioSolutions name. The change unifies Artis' U.S. and European capabilities under a single brand, completing a transatlantic platform that connects proprietary synthetic DNA production directly to advanced therapy development and clinical-grade manufacturing.
Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston
Artis BioSolutions (“Artis”), an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA manufacturing capabilities in Boston utilizing Syngoi Technologies’ (“Syngoi”) proprietary enzymatic platform. This expansion strategically extends Artis’ regional capabilities, integrating with its advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver reliable, scalable, and efficient solutions for its global customer base.
Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy
Artis BioSolutions today announced the appointment of Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer, effective February 9, 2026. Dr. Broderick will lead scientific strategy, advocacy and innovation initiatives across the Artis platform, supporting the company’s mission to build an integrated ecosystem for the development and manufacturing of next-generation genetic medicines.
Artis BioSolutions Announces Agreement to Acquire Syngoi Technologies to Deliver Next Generation Solutions for Synthetic DNA Technology
Artis BioSolutions (“Artis”), a San Diego-based advanced-therapies development and manufacturing company, today announced that it has entered into a definitive agreement to acquire Syngoi Technologies (“Syngoi”), a Spanish biotechnology company pioneering novel enzymatic approaches for manufacturing synthetic DNA technologies.
